Featured Research

from universities, journals, and other organizations

Substantial Improvements In Cancer Trials Not Likely Caused By Placebo Effects

Date:
January 2, 2003
Source:
Journal Of The National Cancer Institute
Summary:
An analysis of placebo effects in randomized double-blinded placebo-controlled trials of cancer treatments has found that placebos are sometimes associated with improved control of symptoms such as pain and appetite but rarely with objective tumor response. The findings appear in a review article in the January 1 issue of the Journal of the National Cancer Institute.

An analysis of placebo effects in randomized double-blinded placebo-controlled trials of cancer treatments has found that placebos are sometimes associated with improved control of symptoms such as pain and appetite but rarely with objective tumor response. The findings appear in a review article in the January 1 issue of the Journal of the National Cancer Institute.

The placebo effect is an effect seen in patients given an intervention, such as a placebo, that has no pharmacologically-mediated action against the disease. Previous studies have suggested that some cancer patients who had received a placebo for pain reported a reduction in pain after the intervention.

To determine the probability that a placebo will lead to improvement of symptoms and tumor response, Gisθle Chvetzoff, M.D., of the Centre Lιon Bιrard in Lyon, France, and Ian F. Tannock, M.D., Ph.D., of the Princess Margaret Hospital in Toronto, reviewed reports of 37 randomized controlled trials that compared a group receiving active treatment with a group receiving a placebo. The authors also reviewed reports of 10 randomized controlled trials that compared a group receiving active treatment plus best supportive care with a group receiving best supportive care alone. Some of the trials looked at individual responses, and other trials looked at group responses.

The researchers found that, in trials that examined average responses for patients in the placebo group, two of six trials reported improvements in pain and one of seven trials reported improvements in appetite. No trials reported improvements in average levels of weight gain, quality of life, or performance status.

In trials that looked at individual response to placebos, 0% to 21% of patients given a placebo showed improvement in pain or decreased use of pain medications, 8% to 27% of patients showed an improvement in appetite, 7% to 17% of patients showed weight gain, and 6% to 14% of patients showed improvement in performance status. By contrast, objective tumor response was observed in 2% to 7% of patients in a placebo group.

In addition, the authors found that the likelihood of symptom improvement in patients receiving best supportive care was similar to that of patients receiving placebo.

"The present review suggests that substantial well-documented patient-reported improvement in symptom control or quality of life (particularly when supported by objective evidence of tumor response) are unlikely due to placebo effects," the authors conclude. They add that they strongly support the use of a double-blind placebo-controlled design for randomized trials whenever possible because such a design can ensure equal conditions in both arms and minimize various types of bias.

In an accompanying editorial, Robert J. Temple, M.D., of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration, points out that only two of 10 trials reported objective tumor responses of more than 2% in the placebo group (one trial reported 7%). He says that "tumor response rates of more than 10% are unlikely to be seen in an untreated group and can therefore be considered evidence of a drug effect… ."

Temple also notes that in trials looking at symptoms such as pain and appetite, individual patient improvements were seen among people in placebo groups, suggesting that single-arm trials (those that include only a treatment group) are a suboptimal way to assess the benefits of treatment.


Story Source:

The above story is based on materials provided by Journal Of The National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal Of The National Cancer Institute. "Substantial Improvements In Cancer Trials Not Likely Caused By Placebo Effects." ScienceDaily. ScienceDaily, 2 January 2003. <www.sciencedaily.com/releases/2003/01/030102224643.htm>.
Journal Of The National Cancer Institute. (2003, January 2). Substantial Improvements In Cancer Trials Not Likely Caused By Placebo Effects. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2003/01/030102224643.htm
Journal Of The National Cancer Institute. "Substantial Improvements In Cancer Trials Not Likely Caused By Placebo Effects." ScienceDaily. www.sciencedaily.com/releases/2003/01/030102224643.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) — The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) — An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) — Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) — Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins